Conner Tonia L, Vir Pooja, Laing Eric D, Stewart Ian J, Mitre Edward, Pratt Kathleen P
Department of Microbiology, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.
The Henry Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20814, USA.
Antibodies (Basel). 2024 Aug 6;13(3):65. doi: 10.3390/antib13030065.
PURIFY-OBS-1 is an observational study evaluating the safety and efficacy of Seraph 100 Microbind Affinity Blood Filter (Seraph 100) use for COVID-19 patients with respiratory failure admitted to the intensive care unit (ICU). The Seraph 100 is a hemoperfusion device containing heparin-coated beads that can bind to, and reduce levels of, some circulating pathogens and inflammatory molecules. This study evaluated whether treatment with the Seraph 100 affected circulating and mucosal antibody levels in critically ill COVID-19 subjects. SARS-CoV-2 anti-spike and anti-nucleocapsid IgG and IgA levels in serum were evaluated at enrollment and on days 1, 4, 7, and 28 after Seraph 100 application, while anti-spike and nucleocapsid IgG, IgA, and secretory IgA levels in tracheal aspirates were evaluated at enrollment and on days 1, 2, 3, 7, and 28. Serum samples were also collected from the pre- and post-filter lines at 1 and 4 h following Seraph 100 application to evaluate the direct impact of the filter on circulating antibody levels. Treatment with the Seraph 100 did not alter the levels of circulating or mucosal antibodies in critically ill COVID-19 subjects admitted to the ICU.
PURIFY - OBS - 1是一项观察性研究，旨在评估用于入住重症监护病房（ICU）的COVID - 19呼吸衰竭患者的Seraph 100微结合亲和血液滤过器（Seraph 100）的安全性和有效性。Seraph 100是一种血液灌流装置，包含肝素包被的珠子，能够结合并降低某些循环病原体和炎症分子的水平。本研究评估了Seraph 100治疗是否会影响重症COVID - 19受试者的循环和黏膜抗体水平。在入组时以及应用Seraph 100后的第1、4、7和28天评估血清中SARS-CoV-2抗刺突和抗核衣壳IgG及IgA水平，同时在入组时以及第1、2、3、7和28天评估气管吸出物中的抗刺突和核衣壳IgG、IgA及分泌型IgA水平。在应用Seraph 100后1小时和4小时还从滤器前后管路采集血清样本，以评估滤器对循环抗体水平的直接影响。对于入住ICU的重症COVID - 19受试者，使用Seraph 100治疗并未改变其循环或黏膜抗体水平。
